John P. Leonard, MD
@JohnPLeonardMD
Followers
10K
Following
6K
Media
808
Statuses
9K
Doctor for lymphoma patients, researcher, collaborator, professor/division director @Perlmutter_CC @nyulangone Tweets mine RT not=endorsement, he/him/his
NYU Langone Health
Joined November 2014
Here is the big #hairstylesforheroes "reveal" - Nearly $75,000 raised to support the efforts our front line care team! Thanks to all who have supported and not too late to donate! Lots of great looks! #WCMDeptofMed @WeillCornell
https://t.co/s2pQzXFiT4
28
28
370
Immunotherapy is transforming cancer care. At NYU Langone, Dr. Michelle Krogsgaard is engineering immune cells to recognize and destroy cancer—offering hope for cures once thought impossible. Watch to learn more ⬇️ #BehindTheBreakthrough #Immunotherapy
0
1
3
Congratulations @RichPossemato and Michelle Krogsgaard on this great award and impactful project! @Perlmutter_CC @nyugrossman
🛡️ Richard Possemato & Michelle Krogsgaard will investigate how tumors starve T-cells of key nutrients—hindering the immune system’s ability to fight cancer. Their goal: Identify metabolic conditions and genes that could boost T-cells during cancer treatment.
0
0
12
Inspiring and humbling to learn from our next generation of talent with our Hem/Onc fellow extraordinaire Dr Dennis Lee presenting additional exciting data from @DrGarethMorgan1’s lab @nyulangone @Perlmutter_CC analyzing the question around plasma cells in multiple myeloma
Excited about today's presentations in #leukemia #lymphoma and #myeloma at #ASH25 #ASH2025 by our NYU @Perlmutter_CC @nyulangone @NYULH_DeptofMed @nyugrossman faculty and trainees, including these 3 highlighted below!
0
2
5
I had a great conversation with @samyamshon from Perlmutter Cancer Center @Perlmutter_CC and NYU Langone Health @nyulangone @nyugrossman about his #ASH25 #ASH2025 presentation on immunological priming of CAR-T cells with the EZH2 inhibitor tazemetostat in B cell #lymphoma
0
5
25
Intriguing data from my colleague Maher Abdul Hay @Perlmutter_CC @nyulangone on CLN-049, a bispecific against FLT3 in AML, with exciting early clinical results in a very tough therapeutic setting. Great to see early signal for efficacy in this space #ASH25
1
6
14
Great work!
Impressive data by @HayMaher @nyulangone @Perlmutter_CC at #ASH25 presenting the results of an early phase FLT3 #bispecific T-cell engager in #AML showing activity regardless of FLT3 expression or TP53 mutation status!
0
2
12
Excited about today's presentations in #leukemia #lymphoma and #myeloma at #ASH25 #ASH2025 by our NYU @Perlmutter_CC @nyulangone @NYULH_DeptofMed @nyugrossman faculty and trainees, including these 3 highlighted below!
0
7
17
@nyulangone @Perlmutter_CC plasma cell dyscrasia program on 🔥at #ASH25 with @DrGarethMorgan1 lab and clinical research presented all throughout the conference. There he is telling us about it.
It was exciting to hear about my colleague @FaithEDavies1 @Perlmutter_CC @nyulangone presenting her data at #ASH25
0
5
9
Honored to share our work at #ASH25 with Dr. John Leonard. Using AI to improve the diagnosis of mycosis fungoides is an exciting step toward advancing cutaneous lymphoma care. Grateful for the support from @nyulangone and @Perlmutter_CC.
I enjoyed speaking with Mohamed Sharaf from Perlmutter Cancer Center @Perlmutter_CC and NYU Langone Health @nyulangone @nyugrossman regarding his innovative #ASH25 #ASH2025 presentation on using AI and machine learning to diagnose mycosis fungoides (cutaneous T cell # lymphoma)
0
2
5
It was exciting to hear about my colleague @FaithEDavies1 @Perlmutter_CC @nyulangone presenting her data at #ASH25
Always great to see @FaithEDavies1 in clinic at @Perlmutter_CC @nyulangone and looking forward to her presentation today among many from our team# at #ASH25 #ASH2025 !
0
2
9
I enjoyed speaking with Mohamed Sharaf from Perlmutter Cancer Center @Perlmutter_CC and NYU Langone Health @nyulangone @nyugrossman regarding his innovative #ASH25 #ASH2025 presentation on using AI and machine learning to diagnose mycosis fungoides (cutaneous T cell # lymphoma)
1
1
13
Always great to see @FaithEDavies1 in clinic at @Perlmutter_CC @nyulangone and looking forward to her presentation today among many from our team# at #ASH25 #ASH2025 !
0
4
13
Want to work at @Perlmutter_CC and one of the highest ranking health systems in safety and quality? Connect with us at #ASH25
Happy to connect with potential candidates!
0
1
5
Happy to connect with potential candidates!
We are hiring: Stem Cell Transplant/Cellular Therapy/Heme Malignancy Faculty Physicians/Director Will be at @ASH_hematology meeting and happy to meet with interested potential candidates - just contact me directly #ASH25 #ASH2025
https://t.co/A4EZOz8KJM
0
1
6
0
1
4
@JohnPLeonardMD @Perlmutter_CC @nyulangone Thanks Dr. Leonard. Thrilled to be joining NYU next year!
0
1
5
Great to see @steve_shan incoming @Perlmutter_CC @nyulangone hematology oncology fellow at #ASH25 #ASH25 ! I knew him when (he interviewed)! Excited for the future!
1
3
15
I spoke today with Maria Sirenko from Perlmutter Cancer Center @Perlmutter_CC and NYU Langone Health @nyulangone regarding her interesting #ASH25 #ASH2025 presentation on VEXAS syndrome - here is her summary:
1
6
23
Coinciding with our (Audrey Lasry) presentation at #ASH25 today, our pre-print is just out! Years of extensive characterization of myeloid sarcoma from genetic mapping to molecular evolution, sc transcriptomics, spatial analysis, animal modeling and drug targeting! Years of close
biorxiv.org
Myeloid sarcoma, an aggressive extramedullary subtype of acute myeloid leukemia (AML), occurs in ∼10% of patients, and has not yet been included in large-scale genomic studies. The critical biologi...
2
16
74